Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Alone and with Pembrolizumab in HER2-Expressing Urothelial Carcinoma
2022-500030-28-00Phase 2Withdrawn
- Sponsor
- Seagen Inc.
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Seagen Inc. Primary endpoints: Confirmed objective response rate by BICR (primary endpoint 1) and Confirmed objective response rate by BICR (primary endpoint 2). Planned start Dec 2022; status: withdrawn.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-500030-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500030-28-00.